[ Price : $8.95]
An FDA safety signal report for the second quarter shows 14 products for which the agency is investigating potential signals of se...[ Price : $8.95]
FDA sends MedImmune a second complete response letter on motavizumab, this one asking for an additional clinical trial to support ...[ Price : $8.95]
Forest Laboratories and Gedeon Richter report mixed results from an exploratory Phase 2 trial involving the investigational antips...[ Price : $8.95]
FDA extends by three months its review of an Eisai NDA for eribulin mesylate, indicated for treating locally advanced or metastati...[ Price : $8.95]
A federal indictment accuses three former Spectranetics executives and a fourth person of multiple counts involved in illegally im...[ Price : $8.95]
FDA Webview editor Jim Dickinson reviews the Obama change agenda broadly and finds, from FDA to Afghanistan, that it has delivered...[ Price : $8.95]
CDER oncology drugs director Richard Pazdur says the agency is working on new research guidelines to facilitate development of can...